DK1761650T3 - Humant autisme modtagelighedsgen, der koder for PRKCB1 og anvendelser deraf - Google Patents

Humant autisme modtagelighedsgen, der koder for PRKCB1 og anvendelser deraf

Info

Publication number
DK1761650T3
DK1761650T3 DK05766789T DK05766789T DK1761650T3 DK 1761650 T3 DK1761650 T3 DK 1761650T3 DK 05766789 T DK05766789 T DK 05766789T DK 05766789 T DK05766789 T DK 05766789T DK 1761650 T3 DK1761650 T3 DK 1761650T3
Authority
DK
Denmark
Prior art keywords
disorder
gene
autism
diagnosis
prevention
Prior art date
Application number
DK05766789T
Other languages
Danish (da)
English (en)
Inventor
Anne Philippi
Francis Rousseau
Peter Brooks
Joerg Hager
Original Assignee
Integragen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integragen Sa filed Critical Integragen Sa
Application granted granted Critical
Publication of DK1761650T3 publication Critical patent/DK1761650T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK05766789T 2004-07-01 2005-06-30 Humant autisme modtagelighedsgen, der koder for PRKCB1 og anvendelser deraf DK1761650T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58413204P 2004-07-01 2004-07-01
PCT/IB2005/002381 WO2006003523A2 (fr) 2004-07-01 2005-06-30 Gene humain de predisposition a l'autisme codant prkcb1 et procedes d'utilisation

Publications (1)

Publication Number Publication Date
DK1761650T3 true DK1761650T3 (da) 2009-06-29

Family

ID=34982198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05766789T DK1761650T3 (da) 2004-07-01 2005-06-30 Humant autisme modtagelighedsgen, der koder for PRKCB1 og anvendelser deraf

Country Status (10)

Country Link
US (2) US20080193464A1 (fr)
EP (1) EP1761650B1 (fr)
JP (1) JP2008504838A (fr)
AT (1) ATE424469T1 (fr)
AU (1) AU2005258841B2 (fr)
CA (1) CA2571370A1 (fr)
DE (1) DE602005013080D1 (fr)
DK (1) DK1761650T3 (fr)
IL (1) IL179831A (fr)
WO (1) WO2006003523A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1863937B1 (fr) * 2005-03-24 2010-09-22 Integragen Gene humain de susceptibilite a l'autisme codant une proteine transmembrane et ses utilisations
US20070292962A1 (en) * 2006-04-10 2007-12-20 Duke University Methods and compositions for genetic markers for autism
WO2008126932A2 (fr) * 2007-04-09 2008-10-23 Riken Régulation épigénétique de la plasticité du cerveau
WO2009043178A1 (fr) * 2007-10-04 2009-04-09 The Hospital For Sick Children Biomarqueurs pour des troubles du spectre autistique
WO2011022292A2 (fr) * 2009-08-19 2011-02-24 Lunera Research, Inc. Méthode de traitement du trouble bipolaire ou de la dépression à l'aide d'un anti-œstrogène
EP2724721A1 (fr) * 2012-10-26 2014-04-30 Matentzoglu, Konstantin Composition pour utilisation dans le traitement du syndrome d'Angelman et/ou trouble de spectre autistique, l'utilisation d'une telle composition et procédé de fabrication d'un médicament pour le traitement du syndrome d'Angelman et/ou trouble de spectre autistique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1994019478A1 (fr) 1993-02-22 1994-09-01 The Rockefeller University Production de retrovirus exempts d'auxiliaires, a titre eleve par transfection transitoire
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1627043A4 (fr) * 2002-10-23 2006-10-11 Exelixis Inc Gene mapk7 en tant que modulateur de la morphogenese de ramification, et procedes d'utilisation

Also Published As

Publication number Publication date
IL179831A (en) 2011-06-30
ATE424469T1 (de) 2009-03-15
US20100240539A1 (en) 2010-09-23
CA2571370A1 (fr) 2006-01-12
WO2006003523A2 (fr) 2006-01-12
DE602005013080D1 (de) 2009-04-16
US20080193464A1 (en) 2008-08-14
WO2006003523A3 (fr) 2006-05-18
EP1761650A2 (fr) 2007-03-14
AU2005258841B2 (en) 2010-07-01
JP2008504838A (ja) 2008-02-21
WO2006003523A8 (fr) 2006-03-02
AU2005258841A1 (en) 2006-01-12
EP1761650B1 (fr) 2009-03-04
IL179831A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
IL179751A0 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
EP3498729A3 (fr) Cibles thérapeutiques pour la maladie d'alzheimer
ECSP13012609A (es) Composición farmacéutica
DK1761650T3 (da) Humant autisme modtagelighedsgen, der koder for PRKCB1 og anvendelser deraf
MX2011006091A (es) Inhibidores de imidazopirazina syk.
MX2008009947A (es) Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
WO2006087634A3 (fr) Gene humain de susceptibilite a l'autisme codant pour une kinase et utilisations de celui-ci
WO2007132292A3 (fr) Thérapie pour la maladie d'alzheimer
DK1656458T3 (da) Human autisme-susceptibilitetsgen og anvendelser deraf
WO2010011283A3 (fr) Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
DK1863937T3 (da) Humant autisme-susceptibilitetsgen kodende for et transmembranprotein og anvendelser deraf
WO2010000089A8 (fr) Stat3 et tyk2 en tant que cibles de médicaments pour maladies neurodégénératives
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
Rikos et al. TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort
WO2006090288A3 (fr) Genes humains de predisposition a l'autisme codant pour un transporteur de neurotransmetteur et utilisations associees
WO2006003526A8 (fr) Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci
WO2010121834A3 (fr) Famille de kinases irak en tant que nouvelle cible et biomarqueur pour la maladie d'alzheimer
ATE471322T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
FR2856595B1 (fr) Methodes et compositions pour le traitement de deficits cognitifs.
DE602005016676D1 (de) Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas-suszeptibilitätssgen und dessen verwendung
Parshukova et al. PROTEOLYTIC ACTIVITY OF IMMUNOGLOBULINS G OF PATIENTS WITH SCHIZOPHRENIA
ATE487714T1 (de) Imino-oxazolidine und ihre verwendung als antikoagulantien
BRPI0409688A (pt) análise e emprego de polimorfismos par1 para avaliação do risco de doenças cardiovasculares
TH74680B (th) คลอไรท์ในการรักษาโรคการเสื่อมของประสาท